119 related articles for article (PubMed ID: 38615236)
1. Association of serum IL-30 and soluble GP130 with the risk of psoriasis vulgaris.
Shehata RR; Atta SA; Fatma AS; Aml RA; Gomaa AS
Egypt J Immunol; 2024 Apr; 31(2):61-70. PubMed ID: 38615236
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study.
Omar NS; Long X; Xian J; Afewerky HK; Hussain SG; Peng X
J Int Med Res; 2021 Apr; 49(4):3000605211004039. PubMed ID: 33900870
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis.
He Z; Jin L; Liu ZF; Hu L; Dang EL; Feng ZZ; Li QJ; Wang G
Br J Dermatol; 2012 Jul; 167(1):191-3. PubMed ID: 22356196
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of selected Th17 and Th22 cytokines in psoriatic patients.
Michalak-Stoma A; Bartosińska J; Kowal M; Juszkiewicz-Borowiec M; Gerkowicz A; Chodorowska G
Dis Markers; 2013; 35(6):625-31. PubMed ID: 24288431
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris.
Sehat M; Talaei R; Dadgostar E; Nikoueinejad H; Akbari H
Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):179-187. PubMed ID: 29757591
[TBL] [Abstract][Full Text] [Related]
6. Serum level of cytokine IL-30 in psoriatic patients and correlation with disease severity.
Omar NS; Xinxin L; Jiayi X; Hussain SG; Biao PX
J Popul Ther Clin Pharmacol; 2021; 28(1):24-33. PubMed ID: 34476935
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Serum Proinflammatory Cytokine IL-17A and Tight Junction Protein Claudin-1 in Psoriasis.
Xu L; Pan Y; Tang S; Bai J; Wu Y; Qiao J; Fang H
Contrast Media Mol Imaging; 2022; 2022():6092808. PubMed ID: 35340911
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the assembly and activation of the IL-27 signaling complex.
Jin Y; Fyfe PK; Gardner S; Wilmes S; Bubeck D; Moraga I
EMBO Rep; 2022 Oct; 23(10):e55450. PubMed ID: 35920255
[TBL] [Abstract][Full Text] [Related]
9. Enhanced serum interferon-lambda 1 interleukin-29 levels in patients with psoriasis vulgaris.
Fu LX; Chen T; Guo ZP; Cao N; Zhang LW; Zhou PM
An Bras Dermatol; 2021; 96(4):416-421. PubMed ID: 34030913
[TBL] [Abstract][Full Text] [Related]
10. IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients.
de Oliveira PS; Cardoso PR; Lima EV; Pereira MC; Duarte AL; Pitta Ida R; Rêgo MJ; Pitta MG
Mediators Inflamm; 2015; 2015():819149. PubMed ID: 26351408
[TBL] [Abstract][Full Text] [Related]
11. Serum Levels of IL-10 and IL-22 Cytokines in Patients with Psoriasis.
Sobhan MR; Farshchian M; Hoseinzadeh A; Ghasemibasir HR; Solgi G
Iran J Immunol; 2016 Dec; 13(4):317-323. PubMed ID: 27999243
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity.
Jacob SE; Nassiri M; Kerdel FA; Vincek V
Mediators Inflamm; 2003 Oct; 12(5):309-13. PubMed ID: 14760939
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokines and growth factor levels in Japanese patients with psoriasis.
Takahashi H; Tsuji H; Hashimoto Y; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2010 Aug; 35(6):645-9. PubMed ID: 19843085
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.
Kyriakou A; Patsatsi A; Vyzantiadis TA; Sotiriadis D
J Immunol Res; 2014; 2014():467541. PubMed ID: 25759829
[TBL] [Abstract][Full Text] [Related]
16. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia.
Wang Y; Lewis DF; Gu Y; Zhao S; Groome LJ
Hypertension; 2011 Feb; 57(2):336-42. PubMed ID: 21173340
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity.
Arican O; Aral M; Sasmaz S; Ciragil P
Mediators Inflamm; 2005 Oct; 2005(5):273-9. PubMed ID: 16258194
[TBL] [Abstract][Full Text] [Related]
18. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis.
Shimauchi T; Hirakawa S; Suzuki T; Yasuma A; Majima Y; Tatsuno K; Yagi H; Ito T; Tokura Y
J Dermatol; 2013 Oct; 40(10):805-12. PubMed ID: 23915382
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen.
Borska L; Andrys C; Krejsek J; Hamakova K; Kremlacek J; Ettler K; Fiala Z
Int J Dermatol; 2008 Aug; 47(8):800-5. PubMed ID: 18717859
[TBL] [Abstract][Full Text] [Related]
20. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.
Mitsuyama K; Tomiyasu N; Suzuki A; Takaki K; Takedatsu H; Masuda J; Yamasaki H; Matsumoto S; Tsuruta O; Toyonaga A; Sata M
Clin Exp Immunol; 2006 Jan; 143(1):125-31. PubMed ID: 16367943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
